Nasopharyngeal Cancer - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 129 Pages - SKU: GMD6775967
|
|
Nasopharyngeal Cancer - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Nasopharyngeal Cancer - Pipeline Review, H1 2012', provides an overview of the Nasopharyngeal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Nasopharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer. 'Nasopharyngeal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Nasopharyngeal Cancer.
- A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nasopharyngeal Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Nasopharyngeal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Nasopharyngeal Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Nasopharyngeal Cancer
- Nasopharyngeal Cancer Therapeutics under Development by Companies
- Nasopharyngeal Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Nasopharyngeal Cancer Therapeutics - Products under Development by Companies
- Nasopharyngeal Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Nasopharyngeal Cancer Therapeutics Development
- F. Hoffmann-La Roche Ltd.
- Sanofi-Aventis
- YM BioSciences Inc.
- Cyclacel Pharmaceuticals Inc.
- Jiangsu Hengrui Medicine Co., Ltd.
- Biotech Pharmaceuticals Co., Ltd.
- Nasopharyngeal Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Seliciclib - Drug Profile
- Vorinostat + Capecitabine - Drug Profile
- Cetuximab + Cisplatin + Radiotherapy - Drug Profile
- Cisplatinum + Radiotherapy - Drug Profile
- Xeloda + Oxaliplatin - Drug Profile
- Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile
- Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
- Cisplatin + Xeloda + Radiation Therapy - Drug Profile
- GW786034 - Drug Profile
- Carboplatin + Paclitaxel - Drug Profile
- Taxotere + Cisplatin + Radiation Therapy - Drug Profile
- Taxotere + Cisplatin + 5-Fluorouracil - Drug Profile
- Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
- Docetaxel + Cisplatin - Drug Profile
- Bevacizumab + Docetaxel + Cisplatin / Carboplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
- Radiotherapy + Cisplatin + Fluorouracil - Drug Profile
- Docetaxel + Cisplatin + Fluorouracil - Drug Profile
- TheraCIM - Drug Profile
- Gemcitabine + Carboplatin - Drug Profile
- Velcade - Drug Profile
- Foscan - Drug Profile
- Docetaxel + Cisplatin + 5-Fluorouracil + Radiotherapy - Drug Profile
- Cisplatin + 5-Fluorouracil + Celecoxib + Radiation Therapy - Drug Profile
- Cisplatin + Radiation Therapy - Drug Profile
- Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile
- Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile
- Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile
- Paclitaxel + Carboplatin + Cisplatin + Amifostine Trihydrate + Radiation Therapy - Drug Profile
- Bevacizumab + Cisplatin + Fluorouracil - Drug Profile
- Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
- Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
- Adriamycin + Lomustine - Drug Profile
- Amifostine Trihydrate + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
- Cisplatin + Radiation Therapy - Drug Profile
- Nedaplatin + Radiation Therapy - Drug Profile
- Modified Vaccinia Ankara Vaccine - Drug Profile
- Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
- Axitinib - Drug Profile
- Sunitinib + Cisplatin + Gemcitabine - Drug Profile
- Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile
- VTX-2337 + Cetuximab - Drug Profile
- Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile
- LBH589 + RAD001 - Drug Profile
- MK2206 - Drug Profile
- Cisplatin + Radiation Therapy - Drug Profile
- Famitinib - Drug Profile
- SOX - Drug Profile
- MK-2206 - Drug Profile
- Docetaxel + Cisplatin + Radiation Therapy - Drug Profile
- Famitinib + Cisplatin + Radiation Therapy - Drug Profile
- Nasopharyngeal Cancer Therapeutics - Drug Profile Updates
- Nasopharyngeal Cancer Therapeutics - Discontinued Products
- Nasopharyngeal Cancer Therapeutics - Dormant Products
- Nasopharyngeal Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Nasopharyngeal Cancer, H1 2012
- Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
- F. Hoffmann-La Roche Ltd., H1 2012
- Sanofi-Aventis, H1 2012
- YM BioSciences Inc., H1 2012
- Cyclacel Pharmaceuticals Inc., H1 2012
- Jiangsu Hengrui Medicine Co., Ltd., H1 2012
- Biotech Pharmaceuticals Co., Ltd., H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Nasopharyngeal Cancer Therapeutics - Drug Profile Updates
- Nasopharyngeal Cancer Therapeutics - Discontinued Products
- Nasopharyngeal Cancer Therapeutics - Dormant Products
- Nasopharyngeal Cancer Therapeutics - Dormant Products (Contd..1)
- Nasopharyngeal Cancer Therapeutics - Dormant Products (Contd..2)
- List of Figures
- Number of Products under Development for Nasopharyngeal Cancer, H1 2012
- Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|